Leucine-rich repeat kinase 2 (LRRK2) ankyrin domain (LRRK2 ANK)

Leucine-rich repeat kinase 2 (LRRK2) is a large, multi-domain enzyme that serves as a major genetic risk factor for Parkinson's disease (PD) [1]. The ankyrin (ANK) domain is a structural motif located in the N-terminal region of LRRK2, consisting of approximately seven ankyrin repeats that facilitate protein-protein interactions and intracellular localization [1, 3]. This domain is essential for the recruitment of LRRK2 to cellular membranes and its interaction with regulatory proteins and substrates, such as Rab GTPases, which are critical for vesicular trafficking and lysosomal function [3, 4]. Mutations in the LRRK2 gene, most notably the G2019S mutation, lead to increased kinase activity, which is linked to neurodegeneration and the accumulation of alpha-synuclein [2, 4]. While most current therapeutic efforts, such as the development of BIIB122 (DNL151), focus on inhibiting the LRRK2 kinase domain, the ANK domain remains a vital area of research for understanding the protein's scaffolding roles and potential alternative targeting strategies [2, 3]. Clinical trials are currently investigating LRRK2 inhibitors for their potential to modify disease progression in both familial and idiopathic Parkinson's disease patients [2].

Other names

ANK domain of LRRK2Dardarin ankyrin domainLRRK2 ankyrin repeat domainPARK8 ankyrin domain

Inhibition of LRRK2 kinase activity to reduce the hyperphosphorylation of Rab GTPases and other substrates, thereby restoring normal lysosomal and vesicular trafficking pathways [2, 4].